Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX208 + trametinib in advanced solid tumors
NCT04965220Phase 1Unknown
- Sponsor
- Henlius
- Start
- Jan 2022
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of HLX208 in solid tumor, anaplastic thyroid cancer (ATC), brain tumor and 1 more (4 cohorts), sponsored by Henlius. Primary endpoint: Maximum Tolerated Dose. Status: unknown.
02
Drugs
HLX208
03
Conditions
solid tumoranaplastic thyroid cancer (ATC)brain tumorcolorectal cancer (CRC)
Beyond the preview
Go deeper on NCT04965220.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04965220.